MilliporeSigma announced an additional investment of $50 million to build a robust manufacturing and distribution platform in Asia over a span of two years. This investment follows the company’s November 2016 announcement of its $100 million Life Science investment in Nantong, China.
“In biopharmaceutical research, time is of the essence,” said Udit Batra, chief executive officer, MilliporeSigma. “Our investments in the important Asian markets of South Korea, India and China ensure that our customers have ready access to the products needed to develop new therapies and biosimilars that accelerate access to health for people everywhere.”
MilliporeSigma’s new South Korea manufacturing and distribution center, located in the Songdo district of Incheon, will include an infrastructure to facilitate the supply of its products to customers in Korea and advanced cell culture media manufacturing capabilities (imMEDIAte Advantage® Custom Media). Occupying a land area of 109,000 square feet, the new site is expected to be fully operational in Q4 2019. Another new center, located in Mumbai, India is expected to be completed in 2019, and will be 129,000 square feet with added capacity.
